Skip to Main Content

APNA 19th Clinical Psychopharmacology Institute

Adapting & Innovating: Psychopharmacologic Nursing Care in the Midst of Crisis
June 10-13, 2021 / Offered Virtually

“Other pharma-oriented conferences I have attended focused on biomedical processes and products, while CPI focuses on the experience of human problems and the science behind ways to help. APNA CPI elevates my practice to serve my patients better.”
– Anthony Peckham, PMHNP-BC

Master your psychopharmacologic nursing practice across the lifespan.

The APNA Clinical Psychopharmacology Institute (CPI) delivers psychopharmacology updates to professionals looking to provide the best possible care to their patients. CPI prioritizes the integration of psychopharmacology and neuroscience into clinical practice. It offers the scientific base for treatment decisions and addresses the context of care within the nurse/consumer/family relationship.

 

Join other providers like you.

The APNA Clinical Psychopharmacology Institute is appropriate for RN-PMH and advanced practice psychiatric nurses – especially those who administer and/or prescribe medications. Because CPI is planned for nurses, by nurses, the program provides a depth and breadth of scientific information tailored to the challenges inherent in psychiatric-mental health nursing practice. All other health care providers interested in psychopharmacology are welcome for advanced study, especially fellow nurses, primary care physicians, psychiatrists, psychologists, and pharmacists.

 

The content of this CNE activity pertains to pharmacology. Because states’ requirements may vary, contact your Board of Nursing for more information.

The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Joshua Gordon, MD, PhD

Director, National Institutes of Mental Health
Thursday, June 10

Dr. Gordon oversees an extensive research portfolio of basic and clinical research at NIMH. His own research focuses on the effects of genes that predispose to psychiatric illnesses.

George F Koob headshot resize

George Koob, PhD

Director, National Institute on Alcohol Abuse & Alcoholism
Friday, June 11

An expert in the neurobiology of alcohol and drug addiction, Dr. Koob is recognized internationally for his work with alcohol and stress, including prevention and treatment.

NinaSchooler

Nina R. Schooler, PhD

Professor of Psychiatry and Behavioral Sciences, State University of New York Downstate Health Sciences Center
Saturday, June 12

Dr. Schooler works extensively on the long-term course of schizophrenia, particularly with regard to first episode of psychosis, the relationship of psychological and pharmacological treatments, and treatment adherence.